Avantax Advisory Services Inc. Trims Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Avantax Advisory Services Inc. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,709 shares of the medical research company’s stock after selling 497 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Charles River Laboratories International were worth $315,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International in the third quarter worth $59,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 3.2 %

Shares of Charles River Laboratories International stock opened at $161.57 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $273.32. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $165.32 and a 200-day moving average price of $183.30. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of 1,077.13, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRL. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Barclays cut their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).